- Home
- HOOK vs OMH Comparison
HOOK vs OMH Comparison
Compare HOOK & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- OMH
- Stock Information
- Founded
- HOOK 2011
- OMH 2015
- Country
- HOOK United States
- OMH Singapore
- Employees
- HOOK N/A
- OMH N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- OMH Real Estate
- Sector
- HOOK Health Care
- OMH Finance
- Exchange
- HOOK Nasdaq
- OMH Nasdaq
- Market Cap
- HOOK 15.3M
- OMH 13.6M
- IPO Year
- HOOK 2019
- OMH 2023
- Fundamental
- Price
- HOOK $1.20
- OMH $1.54
- Analyst Decision
- HOOK Buy
- OMH Hold
- Analyst Count
- HOOK 4
- OMH 1
- Target Price
- HOOK $10.67
- OMH N/A
- AVG Volume (30 Days)
- HOOK 67.1K
- OMH 578.0K
- Earning Date
- HOOK 08-07-2025
- OMH 07-18-2025
- Dividend Yield
- HOOK N/A
- OMH N/A
- EPS Growth
- HOOK N/A
- OMH N/A
- EPS
- HOOK N/A
- OMH N/A
- Revenue
- HOOK $9,351,000.00
- OMH $7,976,578.00
- Revenue This Year
- HOOK N/A
- OMH $28.40
- Revenue Next Year
- HOOK N/A
- OMH $23.07
- P/E Ratio
- HOOK N/A
- OMH N/A
- Revenue Growth
- HOOK N/A
- OMH 117.53
- 52 Week Low
- HOOK $0.72
- OMH $0.59
- 52 Week High
- HOOK $6.77
- OMH $6.20
- Technical
- Relative Strength Index (RSI)
- HOOK 39.18
- OMH 48.73
- Support Level
- HOOK $1.13
- OMH $1.32
- Resistance Level
- HOOK $1.35
- OMH $1.58
- Average True Range (ATR)
- HOOK 0.06
- OMH 0.10
- MACD
- HOOK -0.01
- OMH 0.04
- Stochastic Oscillator
- HOOK 40.64
- OMH 71.99
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.